Williams Kherkher makes the National Law Journal’s ‘Top 100 Verdicts’ List

Steve Kherkher and the team at Williams Kherkher are proud that their recent $46.5 million-dollar verdict against Monsanto will be recognized by The National Law Journal as one of the Top 100 Verdicts of 2016. Inclusion on the prestigious and highly-coveted list is an honor and the team is proud to be recognized for their work on behalf of individuals who developed Non-Hodgkin’s lymphoma (NHL) due to polychlorinated biphenyls in Monsanto products.

The Top 100 Verdicts list is created each year by VerdictSearch, who scours court records across the nation in search of the largest verdicts, with help from legal practitioners and other ALM publications. The award is based on jury awards only and does not take into account offsets, appeals, or judicial reductions.

To learn more about Williams Kherkher‘s victory, read the story here. For more information on The National Law Journal’s Top 100 Verdicts list, visit the site here.

Ovarian cancer: How common is the disease?

In the U.S., ovarian cancer is considered the fifth most fatal cancer among women, and the most fatal cancer caused by the female reproductive system. According to the American Cancer Society (ACS), a woman’s risk of developing this serious medical condition during her lifetime is approximately 1 in 75.

In 2015, ACS estimated that there will be about 21,290 new cases of ovarian cancer. Tragically, ACS also estimated that approximately 14,180 women will die from the disease. As such, it is important for women, especially those who are over the age of 60 and those who are experiencing signs and symptoms of ovarian cancer, to get themselves tested for accurate diagnosis and prompt treatment.

Unfortunately, some studies suggest that women who have undergone laparoscopic procedures involving a power morcellator are at higher risk of ovarian cancer. To know more about holding the manufacturers of this medical device accountable for these damages, speak with our team of power morcellator attorneys at Williams Kherkher by calling (888) 220-0640 today.

How Risperdal can cause vision loss

Risperdal is an atypical antipsychotic drug widely used to treat symptoms of schizophrenia, irritability in people living with autism, and manic states of bipolar disorder. However, some studies have associated this drug with different adverse effects, including loss of vision.

Atypical antipsychotic drugs are known to block a neurotransmitter called dopamine, which results in overproduction of prolactin (a type of hormone released by the pituitary gland). This overproduction may cause the gland to increase in size, making it more prone to develop benign tumors (pituitary adenomas). As these tumors grow, they may push the optic nerves and cause vision loss.

There are instances when only one of the eyes is affected. But in cases where a tumor pushes the area of the optic bundle where optic nerves from each eye meet, total loss of vision may occur.

If you think Risperdal has caused you or your loved one to suffer from vision loss or any other side effects, our legal team at Williams Kherkher might be able to help you file a claim against the drug manufacturer involved. Call us at (888) 220-0640 today.

Better endometrial cancer prognosis for women who underwent tubal ligation

A new study found that women who have undergone tubal ligation (TL) at a younger age before developing endometrial cancer later in life have a better endometrial cancer prognosis, Medpage Today published on June 20.

The study involved 4,489 women, 27.6% of whom underwent TL at an average of 32 years old. It found that tubal ligated women were less likely to be diagnosed with stage III or IV uterine cancer. Researchers believe that blocking the fallopian tubes through ligation would interrupt the tubal passage of the cancer cells from the uterus. This would halt metastasis of aggressive cancers and would result in an improved prognosis.

The endometrium, or the inside lining of the uterus, is considered among the potential sources of aggressive cancer cells in a woman’s reproductive system.

Women who have undergone a hysterectomy involving a power morcellator are at an increased risk of uterine cancer. To learn if your situation allows you to seek compensation from the medical device manufacturer, speak with an attorney at Williams Kherkher by calling (888) 220-0640 today.

“Rare” uterine sarcoma not rare at all

Power morcellators are devices used to remove non-cancerous uterine fibroids by breaking up the growths into pieces before retrieving it out of the body. Many gynecologists previously recommended the use of a power morcellator when treating uterine growths, despite the fact that uterine sarcoma could be hidden in these presumed benign fibroids.

Uterine sarcomas are cancer cells that develop in the muscles of the uterus or the tissues that support it. Although many assume uterine sarcoma as a rare occurrence, several studies have found that it is not as rare as it is believed to be. In fact, a 1990 study at a hospital in Los Angeles revealed that around 1 in 200 women who underwent uterine fibroid surgeries had hidden sarcoma. The results were later supported by two studies done in 1999 and 2008, which revealed ratios of one-in-462 and one-in-253, respectively.

Undergoing uterine fibroid surgery with a power morcellator can spread uterine sarcoma, thereby exacerbating the condition. At Williams Kherkher, we help power morcellator victims seek compensation from the manufacturers involved. Call us at (800) 220-9341 today.

How Risperdal can cause cardiac arrest

On October 29, 2009, The U.S. National Library of Medicine National Institutes of Health stated that patients using atypical antipsychotic drugs, such as Risperdal, have a dose-related increased risk of sudden cardiac arrest (SCA).

Atypical antipsychotics are a second-generation class of drugs designed to treat schizophrenia and bipolar disorder. This type of drug was promoted as a safer substitute for the first-generation antipsychotics, which were known to cause a myriad of motor control disabilities. However, both types of antipsychotics are associated with heart disorders, including cardiac arrest. This is because antipsychotics were found to affect the electrical activities of the heart, which may result in heart rhythm abnormalities (arrhythmias) that may ultimately lead to SCA.

If you or your loved one has been harmed after using this drug, a qualified and assertive product liability attorney at Williams Kherkher might be able to help you file a private action against the drug company involved. To see if your situation qualifies for such action, call our office at (888) 220-0640 today.

Risperdal and the risk of pancreatitis

Although Risperdal has been approved to treat symptoms of autism, bipolar disorder, and schizophrenia, several clinical studies have suggested the drug may cause severe side-effects. In fact, a 2003 article published in Pharmacotherapy noted an increased incidence of pancreatitis among various atypical antipsychotics, including Risperdal.

Pancreatitis, or the inflammation of the pancreas, occurs when digestive enzymes are activated in the pancreas instead of the small intestine. Characteristic symptoms are abdominal pain that may radiate to the back, nausea and vomiting. Due to its many life-threatening complications, such as kidney failure, severe lung dysfunction, dehydration, and shock, pancreatitis is regarded a medical emergency that requires immediate hospitalization and monitored care.

Our dedicated team of pharmaceutical defect attorneys at Williams Kherkher have been helping Risperdal victims file claims against the drug manufacturer if they suffer from complications caused by this potentially harmful medication. To see if we can put our experience to work for you, call our offices at (888) 220-0640 today.

MMA to prohibit testosterone therapy for fighters

Mixed Martial Arts (MMA) sports players are now prohibited from using testosterone therapy by the athletic commission, according to a news report on March 12.

The ban of testosterone therapy for MMA fighters was pushed by the Nevada State Athletic Commission after some aging fighters in the Ultimate Fighting Championship (UFC) were allowed to use Testosterone Replacement Therapy (TRT). The therapy reportedly makes fighters able to be more successful at an older age by slowing the aging process.

Research has shown that persons who used steroids during their younger years may experience low testosterone levels as they get older, therefore resulting in the need for TRT.

Unfortunately, testosterone supplements also heighten the risk of a person having a heart attack or stroke. If you have suffered health problems as a result of using low-T supplements, call (888) 220-0640. Our legal team at Williams Kherkher can evaluate your situation and possibly help you pursue legal action to get the compensation you need.

Pradaxa Manufacturers Worried by Internal Study

Atrial fibrillation is a common disorder among people with irregular heartbeats. Patients who suffer from atrial fibrillation run a high risk of experiencing stroke, heart attack, and pulmonary embolism. In order to prevent the occurrence of these medical emergencies, physicians often prescribe an anticoagulant, like Pradaxa, to prevent dangerous blood clotting.

However, since its market release in 2010, Pradaxa has been linked to nearly 1,000 deaths related to excessive bleeding. Physicians are especially concerned about Pradaxa’s bleeding risks because, unlike older anticoagulants like warfarin, Pradaxa doesn’t have an antidote to counteract its blood thinning properties in emergency situations.

Though Pradaxa has caused excessive bleeding in some people, it has proved ineffective as an anticoagulant in other patients. Researchers cite individual patients’ metabolisms to explain the disparity in the drug’s efficacy.  In fact, a recent article in the New York Times revealed that the manufacturers of Pradaxa, Boehringer Ingelheim, were worried about an internal research study’s results that indicated that Pradaxa users could benefit from regular blood testing to see whether or not the drug was working. One of the drug’s more marketable qualities was that it didn’t require regular blood testing, which older anticoagulants required, to prove efficacy. Recently unsealed legal documents have indicated that not only did some people within Boehringer Ingelheim pressure the researcher who published this study to revise some of its findings, but others suggested the study be “quashed altogether.”

In the few years that Pradaxa has been available to patients, it has sold more that $2 billion worth of the anticoagulant.

The attorneys of Williams Kherkher are investigating the claims of individuals who have been affected negatively by Pradaxa. If you or someone you know has been injured by this drug, call our offices at (888) 220-0640 to speak with a member of our legal team.

Texas City Fuel Fire at a BP Refinery

Earlier today, a BP spokesman and officials from Texas City reported that a fire broke out in a residual hydro treater unit at the oil company’s refinery in Texas City.

While no cause has yet been discovered for the fire and the fire was still being dealt with around 2:30 p.m., about an hour after the initial report of the fire, no refinery workers are reported as missing or trapped in the building. At the time of the report, there were also no injuries reported.

Fortunately, the workers at this BP refinery were able to escape physical injury; however, fires and explosions can be devastating accidents in which many people can sustain serious injuries. If you or a loved one has suffered harm in a similar situation or due to a fire that occurred as a result of someone else’s negligence, call a Houston personal injury lawyer from Williams Kherkher at (888) 220-0640 to discuss your legal options.

SEO for Lawyers